PCM
TVRD

Prelude Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Prelude Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11
Closed -$6K – 1945
2017
Q2 		$6K Buy
+11
New +$6.98K ﹤0.01% 1455

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's TVRD Position: Q1 2020 in Review

Prelude Capital Management sold out of Tvardi Therapeutics (TVRD) in Q1 2020, closing a stake of 3 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in TVRD in Q3 2015 and held it in 6 quarters. The position peaked at $172K in Q4 2016. 133 funds tracked by Wall St. Rank hold TVRD as of Q1 2020.

  • Prelude Capital Management reported no remaining Tvardi Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 3 Tvardi Therapeutics shares in Q1 2020, an estimated $1K.
  • Prelude Capital Management first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 6 quarters.
  • Prelude Capital Management's Tvardi Therapeutics position peaked at $172K in Q4 2016.
  • 133 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.